BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3915189)

  • 1. Drug action on ribonucleotide reductase.
    Cory JG; Carter GL
    Adv Enzyme Regul; 1985; 24():385-401. PubMed ID: 3915189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
    Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
    Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleotide reductase as a chemotherapeutic target.
    Cory JG
    Adv Enzyme Regul; 1988; 27():437-55. PubMed ID: 3074632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
    Carter GL; Cory JG
    Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
    Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
    Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
    Sato A; Bacon PE; Cory JG
    Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
    Tihan T; Elford HL; Cory JG
    Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
    Weckbecker G; Weckbecker A; Lien EJ; Cory JG
    J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
    Cory AH; Samano V; Robins MJ; Cory JG
    Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamine.
    FitzGerald GB; Wick MM
    Biochem Pharmacol; 1985 Feb; 34(3):353-60. PubMed ID: 3882092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting the mRNA levels for the non-heme iron and effector-binding subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1992; 32():227-40. PubMed ID: 1496919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
    Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
    Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies directed toward testing the "channeling" hypothesis--ribonucleotides----DNA in leukemia L1210 cells.
    Chiba P; Bacon PE; Cory JG
    Biochem Biophys Res Commun; 1984 Sep; 123(2):656-62. PubMed ID: 6435617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase.
    Carter GL; Thompson DP; Cory JG
    Cancer Commun; 1989; 1(1):13-20. PubMed ID: 2701080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
    Cory AH; Hertel LW; Kroin JS; Cory JG
    Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
    Somerville L; Cory AH; Cory JG
    In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
    Giacca M; Borella S; Calderazzo F; Bianchi LC; D'Agaro P; Rampazzo C; Bianchi V; Reichard P
    AIDS Res Hum Retroviruses; 1996 May; 12(8):677-82. PubMed ID: 8744578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.